In the US, Aptar Digital Health, a provider of digital health solutions, has announced its acquisition of Healint, a Singapore-based company specialising in multimodal health and the generation of real-world evidence for improving treatment outcomes and expediting clinical trials.
According to a press release, Aptar is hoping that the acquisition will align with its strategy to “broaden its portfolio in neurology and strengthen its global footprint for digital health deployment”.
Together, expanded capabilities will include patient community management, patient activation, AI-based data collection, and digital diagnostics. Healint’s expertise in accelerating clinical studies will also be integral to advancing Aptar’s existing solutions to “provide additional value to pharmaceutical customers”.
Sai Shankar, president of Aptar Digital Health, said of the acquisition: “We are excited to welcome the Healint team and expand Aptar Digital Health’s product portfolio and capabilities to clinical trial management. With Healint, we now have the in-house expertise to cover the entire lifecycle of a drug, positioning Aptar Digital Health as a prominent leader in digital health for Central Nervous System conditions.”
Integration of Healint into Aptar Digital Health’s operations is to begin immediately, with Aptar planning to “scale up Healint’s platform to adjacent therapeutic indications in neurology and immunology, and strengthen its current offering by adding new services such as clinical trial management tools”.
In related news, Singapore-based AI solution provider Qritive has announced an upcoming collaboration with three diagnostic centres and hospitals in India: Metropolis Healthcare, the Rajiv Gandhi Cancer Institute and CŌRE Diagnostics.
